Editas Medicine, Inc.

For the period ended Sep 30, 2025. Filed Nov 10, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 10, 2025

EDIT$2.51-8.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity for the

Condensed Consolidated Statements of Stockholders’ Equity

(amounts in thousands, except share data)

Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2024	82,734,696	$8	$1,602,441	$268	$(1,468,443)	$134,274
Issuance of common stock from at-the-market equity offering, net	706,236	—	1,435	—	—	$1,435
Vesting of restricted common stock awards	268,604	—	—	—	—	—
Stock-based compensation expense	—	—	2,979	—	—	2,979
Unrealized loss on marketable debt securities	—	—	—	(180)	—	(180)
Net loss	—	—	—	—	(76,088)	(76,088)
Balance at March 31, 2025	83,709,536	$8	$1,606,855	$88	$(1,544,531)	$62,420
Issuance of common stock from at-the-market equity offering, net	3,419,836	1	7,184	—	—	7,185
Stock-based compensation expense	—	—	2,664	—	—	2,664
Vesting of restricted common stock awards	102,894	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	156,159	—	228	—	—	228
Unrealized loss on marketable debt securities	—	—	—	(73)	—	(73)
Net loss	—	—	—	—	(53,235)	(53,235)
Balance at June 30, 2025	87,388,425	$9	$1,616,931	$15	$(1,597,766)	$19,189
Issuance of common stock from at-the-market equity offering, net	5,799,178	—	17,147	—	—	17,147
Exercise of stock options	12,130	—	21	—	—	21
Stock-based compensation expense	—	—	2,228	—	—	2,228
Vesting of restricted common stock awards	64,688	—	—	—	—	—
Unrealized loss on marketable debt securities	—	—	—	(15)	—	(15)
Net loss	—	—	—	—	(25,117)	(25,117)
Balance at September 30, 2025	93,264,421	$9	$1,636,327	$—	$(1,622,883)	$13,453

Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance at December 31, 2023	81,767,263	$8		$1,580,241		$198		$(1,231,350)		$349,097
Exercise of stock options	21,975	—		192		—		—		192
Vesting of restricted common stock awards	445,713	—		—		—		—		—
Stock-based compensation expense	—	—		7,585		—		—		7,585
Unrealized loss on marketable debt securities	—	—		—		(524)		—		(524)
Net loss	—	—		—		—		(61,950)		(61,950)
Balance at March 31, 2024	82,234,951	$8		$1,588,018		$(326)		$(1,293,300)		$294,400
Stock-based compensation expense	—	—		5,010		—		—		5,010
Vesting of restricted common stock awards	121,643	—		—		—		—		—
Issuance of common stock under employee stock purchase plan	72,920	—		322		—		—		322
Unrealized loss on marketable debt securities	—	—		—		(116)		—		(116)
Net loss	—	—		—		—		(67,607)		(67,607)
Balance at June 30, 2024	82,429,514	$8		$1,593,350		$(442)		$(1,360,907)		$232,009
Vesting of restricted common stock awards	109,110		—		—		—		—		—
Stock-based compensation expense	—		—		4,802		—		—		4,802
Unrealized gain on marketable debt securities	—		—		—		964		—		964
Net loss	—		—		—		—		(62,141)		(62,141)
Balance at September 30, 2024	82,538,624	$8		$1,598,152		$522		$(1,423,048)		$175,634

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.